Meriofert Pfs (Follicle-Stimulating Hormone, Luteinising Hormone)

FSH and LH bind to specific receptors on ovarian granulosa and theca cells. FSH stimulates granulosa cell proliferation and estradiol production, while LH promotes androgen synthesis in theca cells and supports the final maturation of the dominant follicle. Together they replicate the natural pituitary surge that leads to ovulation.

The dose of Meriofert Pfs is individualized. A qualified reproductive specialist evaluates the patient’s hormonal profile, ovarian reserve, and treatment goals, then prescribes the appropriate amount and schedule. Dosing may be adjusted based on monitoring of follicular response and estradiol levels.

Meriofert Pfs is not intended for use during an established pregnancy, and its safety in breastfeeding women has not been established. The product is typically administered before conception, and pregnancy testing is required before each treatment cycle. Use during pregnancy or lactation should only occur under specialist supervision.

To order Meriofert Pfs, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics where required) and any necessary import documentation.

Meriofert Pfs combines both FSH and LH in a single injectable formulation, which can simplify treatment regimens compared with using separate FSH‑only or LH‑only preparations. Its EU‑origin manufacturing follows stringent GMP standards, offering comparable efficacy and safety to other licensed gonadotropin brands while providing the convenience of a combined product.

Meriofert Pfs must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product is inadvertently exposed to temperatures outside this range, it should not be used and a replacement should be requested.

Meriofert Pfs is supplied as a sterile injectable solution for subcutaneous injection. The medication is typically drawn into a syringe and injected into the subcutaneous tissue of the abdomen or thigh, following the dosing schedule prescribed by the treating physician. Proper aseptic technique and patient education are essential.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal distension, fluid accumulation, and respiratory compromise, as well as rare thromboembolic events and severe allergic reactions such as anaphylaxis. Patients should be monitored closely for early signs of these complications.

Meriofert Pfs is contraindicated in individuals with active ovarian cysts, uncontrolled thyroid disease, estrogen‑dependent tumors, or known hypersensitivity to any component of the formulation. It should also be avoided in patients who are already pregnant or who have a confirmed allergy to gonadotropin preparations.